{"organizations": [], "uuid": "caacbfc11ac4d5b7b333c5dc6e07fe794b7a0975", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/11", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/01/pr-newswire-c-o-r-r-e-c-t-i-o-n--curis-inc.html", "country": "US", "domain_rank": 767, "title": "/C O R R E C T I O N -- Curis, Inc./", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-01T15:00:00.000+02:00", "replies_count": 0, "uuid": "caacbfc11ac4d5b7b333c5dc6e07fe794b7a0975"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/01/pr-newswire-c-o-r-r-e-c-t-i-o-n--curis-inc.html", "ord_in_thread": 0, "title": "/C O R R E C T I O N -- Curis, Inc./", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "lexington", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "curis", "sentiment": "negative"}, {"name": "curis, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "In the news release, Curis to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018, issued 01-Mar-2018 by Curis, Inc. over PR Newswire, we are advised by the company that the dial-in numbers in the second paragraph have been updated. The complete, corrected release follows:\nCuris to Release Fourth Quarter and Year-End 2017 Financial Results and Hold Conference Call on March 8, 2018\nLEXINGTON, Mass., March 1, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and year-end 2017 financial results on Thursday, March 8, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST.\nTo access the live conference call, please dial 1-877-870-4263 from the United States or 1-412-317-0790 from other locations, shortly before 8:30 a.m. EST. A corresponding webcast of the conference call can be accessed by visiting https://www.webcaster4.com/Webcast/Page/1827/24814 . The conference call can also be accessed on the Curis website at www.curis.com in the Investors section.\nAbout Curis, Inc.\nCuris is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing ErivedgeÂ® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com .\nView original content: http://www.prnewswire.com/news-releases/curis-to-release-fourth-quarter-and-year-end-2017-financial-results-and-hold-conference-call-on-march-8-2018-300606270.html\nSOURCE Curis, Inc.", "external_links": ["https://www.webcaster4.com/Webcast/Page/1827/24814", "http://www.prnewswire.com/news-releases/curis-to-release-fourth-quarter-and-year-end-2017-financial-results-and-hold-conference-call-on-march-8-2018-300606270.html", "http://www.curis.com/"], "published": "2018-03-01T15:00:00.000+02:00", "crawled": "2018-03-01T17:05:31.000+02:00", "highlightTitle": ""}